Elevation Oncology, Inc. (ELEV)

NASDAQ: ELEV · IEX Real-Time Price · USD
1.02
+0.02 (2.00%)
Feb 1, 2023, 10:59 AM EST - Market open
2%
Market Cap 23.77M
Revenue (ttm) n/a
Net Income (ttm) -85.66M
Shares Out 23.30M
EPS (ttm) -3.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 391
Open 1.00
Previous Close 1.00
Day's Range 1.00 - 1.02
52-Week Range 0.72 - 5.20
Beta n/a
Analysts Buy
Price Target 4.93 (+383.33%)
Earnings Date Mar 2, 2023

About ELEV

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 48
Stock Exchange NASDAQ
Ticker Symbol ELEV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ELEV stock is "Buy." The 12-month stock price forecast is $4.93, which is an increase of 383.33% from the latest price.

Price Target
$4.93
(383.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.

Other symbols: EDITFATEIPSCJNJYMAB
6 days ago - MarketBeat

Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients...

3 weeks ago - PRNewsWire

Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition

Prioritizing the development of EO-3021, a potential best-in-class ADC targeting Claudin18.2, and additional pipeline programs including those through its existing partnership with Caris Life Sciences...

3 weeks ago - PRNewsWire

Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit

NEW YORK , Nov. 30, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomic...

2 months ago - PRNewsWire

Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

On track to report additional interim seribantumab data from the Phase 2 CRESTONE study in the first half of 2023 Preparations are underway to initiate a Phase 1 clinical trial of EO-3021 in the US in...

3 months ago - PRNewsWire

Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Presented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across all tumor types harboring NRG1 fusions Ser...

6 months ago - PRNewsWire

Elevation Oncology to Participate at the Wedbush PacGrow Healthcare Conference

NEW YORK , Aug. 3, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

6 months ago - PRNewsWire

Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures

Initial tranche supports the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and execution of Company's pipeline NEW YORK , July 28, 2022 /PRNewswire/ -...

6 months ago - PRNewsWire

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801) Expands pipeline to now include two clinical stage precision oncology candidates for patients...

6 months ago - PRNewsWire

Elevation Oncology to Participate at Cowen's 3rd Annual Oncology Innovation Summit

NEW YORK , June 1, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

8 months ago - PRNewsWire

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

Positive initial data support the potential of seribantumab to induce deep and durable benefit for patients with tumors harboring NRG1 fusions Clinical activity observed includes a 33% response rate w...

8 months ago - PRNewsWire

Why Elevation Oncology Stock Is Rising

Elevation Oncology Inc (NASDAQ: ELEV) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track designation to seribantumab for the tumor...

9 months ago - Benzinga

Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene Fusions

NEW YORK , May 25, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

9 months ago - PRNewsWire

Elevation Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Initial seribantumab clinical data from Phase 2 CRESTONE study selected for oral presentation at ASCO 2022 David Dornan, PhD appointed Chief Scientific Officer, bringing deep oncology R&D and drug dev...

9 months ago - PRNewsWire

Elevation Oncology Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022

NEW YORK , April 27, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomi...

10 months ago - PRNewsWire

Elevation Oncology Appoints David Dornan, Ph.D., as Chief Scientific Officer

NEW YORK, March 14, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomic...

11 months ago - PRNewsWire

Elevation Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

NEW YORK, March 3, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

11 months ago - PRNewsWire

Elevation Oncology to Participate at Upcoming Virtual Investor Conferences

NEW YORK, March 1, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

1 year ago - PRNewsWire

Elevation Oncology Highlights 2021 Achievements and Outlines Expected 2022 Milestones

NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

1 year ago - PRNewsWire

Elevation Oncology to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomical...

1 year ago - PRNewsWire

Elevation Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomical...

1 year ago - PRNewsWire

Elevation Oncology to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

1 year ago - PRNewsWire

Elevation Oncology Reports Third Quarter 2021 Financial Results

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

1 year ago - PRNewsWire

Elevation Oncology Announces the Promotion of Valerie Malyvanh Jansen, M.D., Ph.D., to Chief Medical Officer

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

1 year ago - PRNewsWire

Elevation Oncology's Seribantumab Included as Part of a Case Series Presentation at the Australasian Gastro-Intestinal Trials Group 2021 Annual Scientific Meeting

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomica...

1 year ago - PRNewsWire